FDA conditionally approves drug for canine neuropathic painMay 13, 2026Liavium-CA1 is indicated for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. The drug, with the active ingredient pregabalin, reduces the release of neurotransmitters that send pain signals in the spinal cord.
Education Center - SponsoredVector-Borne Disease Coming to a Neighborhood Near You: Which Tests to Reach For, and Why?by • AntechWhether it’s a screening to identify exposure to tick-borne pathogens, or a broad molecular diagnostic panel to help with acute disease detection or confirm the presence of genetic material, these options empower veterinary teams, guide treatment, and support antimicrobial stewardship.
